Employees: 517
Size TTY Biopharm (4105.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $615M, the 372nd largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$82.40 on 18 Nov 2026.
Performance Over six months the shares gained 9.7%, against -26.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 4.6% over the last twelve months (peer median +4.7%); the operating margin is 28.5% (peer median 4.2%).
Valuation It trades at 10.2× forward earnings against a peer median of 32.7× (3rd cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.8 points above its cost of capital (5.0% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$6.81B | NT$6.45B | NT$5.90B | NT$5.50B | NT$5.06B |
| Revenue growth | — | +9% | +7% | +9% | — |
| Gross profit | NT$3.88B | NT$3.67B | NT$3.36B | NT$3.22B | NT$2.96B |
| EBITDA | NT$2.15B | NT$1.90B | NT$1.60B | NT$1.57B | NT$1.41B |
| Net income | NT$1.66B | NT$1.56B | NT$1.45B | NT$1.13B | NT$1.09B |
| Free cash flow | NT$1.60B | NT$1.71B | NT$1.26B | NT$1.07B | NT$1.19B |
| Capital expenditure | NT$383M | NT$173M | NT$153M | NT$160M | NT$181M |
| Total debt | NT$1.86B | NT$1.23B | NT$1.76B | NT$1.92B | NT$1.87B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4105.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.0% | -10.7% | 5th highest of 20 |
| 6-month return | +9.7% | -26.6% | 2nd highest of 20 |
| Distance from 52-week high | -5.3% | -41.0% | highest of 20 |
| Revenue growth (TTM) | +4.6% | +4.7% | 8th lowest of 16 |
| Operating margin | 28.5% | 4.2% | 2nd highest of 15 |
| Forward P/E | 10.2× | 32.7× | 3rd cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -8.7% | 9.1% | least demanding of 11 |
| Growth delivered (Del g) | +8.8% | +0.2% | 2nd highest of 11 |
| Hurdle (Req g minus delivered) | -17.5 pp | +12.5 pp | least demanding of 11 |
| ROIC minus cost of capital | +13.8 pp | -4.3 pp | highest of 14 |
| EV / EBITDA | 9.4× | 7.0× | 2nd most expensive of 4 |
| Net debt / EBITDA | -0.4× | 2.9× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | n/a | 36.3% | +16.2% |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Beijing Beilu Pharmaceutical 300016.SZ | China | $641M | -19% | +23% | 11% | 79.7× | 9.1% | +7.9% |